Bausch + Lomb acquires JnJ eye, contact lens drops brand Blink for USD 106.5 million Ruchika Sharma7 July 2023 3:10 PM ISTBausch + Lomb acquired Johnson & Johnson's eye and contact lens drops brand Blink for $106.5 million, marking its second deal in two weeks to...
Janssen reports positive results from phase 2b FRONTIER 1 trial of JNJ-2113 in plaque psoriasis patients Ruchika Sharma6 July 2023 2:30 PM ISTJNJ-2113 is a novel oral IL-23R antagonist peptide that binds with high affinity to the IL-23R and has properties that allow it to be absorbed with...
Cancer plaintiffs drill down on JnJ support for USD 8.9 billion talc deal Ruchika Sharma29 Jun 2023 2:30 PM ISTNew York: The lead negotiators for Johnson & Johnson's proposed $8.9 billion settlement of thousands of talc lawsuits faced intense questioning in...
California man tells jury of getting cancer after using JnJ baby powder Ruchika Sharma27 Jun 2023 3:30 PM ISTA California man suing Johnson & Johnson told jurors on Monday how his life was upended by a cancer diagnosis that he blames on using the...
Teva, Alvotech secure US license date for AVT04, a proposed biosimilar to Stelara Ruchika Sharma13 Jun 2023 1:30 PM ISTIceland: Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and...
Janssen seeks USFDA nod for single tablet combination therapy of Macitentan, Tadalafil for Pulmonary Arterial Hypertension Ruchika Sharma31 May 2023 3:30 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a New Drug Application (NDA) to the U.S. Food...
Janssen Milvexian gets USFDA fast track designation for Ischemic Stroke, Acute Coronary Syndrome, Atrial Fibrillation Ruchika Sharma26 May 2023 3:15 PM ISTRaritan: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that all three prospective indications for milvexian, an ...
Amgen settles patent lawsuit over biosimilar of JnJ's Stelara Ruchika Sharma25 May 2023 2:50 PM ISTStelara is a biologic drug, meaning it is derived from living cells and cannot be exactly duplicated.
J&J agrees to retain all talc related liabilities from litigation in US, Canada Ruchika Sharma30 April 2023 2:30 PM ISTUnited States: Johnson & Johnson said on Thursday it has agreed to retain all talc-related liabilities arising from litigation in the United...
JnJ seeks valuation of up to USD 43 billion in IPO of consumer health unit Kenvue Ruchika Sharma25 April 2023 2:46 PM ISTNew Jersey: Johnson & Johnson said on Monday it was seeking a valuation of up to $42.95 billion in the initial public offering of its...
Janssen gets European Commission nod for AKEEGA to treat metastatic castration resistant prostate cancer with BRCA1/2 mutations Ruchika Sharma22 April 2023 11:32 AM ISTThe EC authorisation, which also marks the first worldwide approval for AKEEGA, is based on results of the randomised, double-blind, placebo...
J&J Gets CDSCO Panel Nod To Conduct Phase IV CT of Ustekinumab Dr. Divya Colin16 April 2023 5:45 PM ISTNew Delhi: In order to evaluate safety of Ustekinumab in Indian subjects with Crohn’s Disease (CD), pharmaceutical major, Johnson & Johnson has...
